샘플 요청 목록

 카트 문의
시장보고서
상품코드
1794454

세계의 갑상선 수질암 시장

Medullary Thyroid Cancer
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 281 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 갑상선 수질암 시장은 2030년까지 22억 달러에 도달

2024년에 14억 달러로 추정되는 세계의 갑상선 수질암 시장은 2024-2030년에 CAGR 7.6%로 성장하며, 2030년에는 22억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 외과 치료는 CAGR 8.9%를 기록하며, 분석 기간 종료시에는 14억 달러에 달할 것으로 예측됩니다. 방사선 치료 분야의 성장률은 분석 기간 중 CAGR 5.2%로 추정됩니다.

미국 시장은 추정 3억 8,330만 달러, 중국은 CAGR 12.1%로 성장 예측

미국의 갑상선 수질암 시장은 2024년에 3억 8,330만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 분석 기간인 2024-2030년 CAGR을 12.1%로, 2030년까지 4억 6,800만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 3.7%와 7.4%로 예측됩니다. 유럽에서는 독일이 CAGR 5.0%로 성장할 것으로 예측됩니다.

세계의 갑상선 수질암 시장 - 주요 동향과 촉진요인 정리

갑상선 악성 종양 중 갑상선 수질암이 독특한 이유는 무엇인가?

갑상선 수질암(MTC)은 갑상선 악성종양 중에서도 독특하고 비교적 드문 형태로, 전 세계 갑상선암 발생의 약 3-4%를 차지합니다. 여포세포에서 발생하는 일반적인 갑상선 유두암이나 여포암과 달리, MTC는 칼시토닌이라는 호르몬을 생산하는 여포주위 C세포에서 발생합니다. 이러한 독특한 기원에 따라 MTC는 생물학적 거동, 임상 양상, 치료 접근법이 다릅니다. MTC는 산발적으로 또는 다발성 내분비종양 2형(MEN2)과 같은 유전성 증후군의 일부로 발생할 수 있으므로 유전자 검사는 진단 및 위험도 분류의 핵심입니다. 칼시토닌 수치와 칼시토닌 항원(CEA) 수치의 상승은 조기 발견 및 질병 모니터링을 위한 중요한 바이오마커가 될 수 있습니다. 분화형 갑상선암과 달리 MTC는 일반적으로 방사성 요오드를 흡수하지 않기 때문에 기존 갑상선암 치료의 효과를 제한합니다. 갑상선 전절제술과 림프절 절제술을 동반하는 경우가 많습니다. 그러나 이 질환은 조기 림프절 전이와 원격 전이, 특히 간과 폐로 전이되기 쉽기 때문에 장기적인 관리가 복잡해집니다. 또한 유전성 환자는 젊은 나이에 발병하는 경우가 많고, 다른 내분비 종양이 발생할 가능성도 있으므로 임상적 복잡성이 더욱 증가합니다. 이러한 요인들로 인해 MTC는 조기 진단, 환자 개개인에 맞는 치료 전략, 평생 모니터링의 필요성이 강조되며, 임상적으로 관리하기 가장 어려운 갑상선암 중 하나입니다.

분자생물학과 유전자 검사의 발전은 진단과 위험 평가에 어떤 변화를 가져오고 있는가?

분자생물학 및 유전자 검사의 발전으로 갑상선 수질암에 대한 이해가 크게 향상되어 진단과 위험도 평가에 필수적인 요소로 자리 잡았습니다. 특히 MEN 2A와 MEN 2B와 같은 가족성 증후군과 관련된 사례에서 RET 원 유전자 돌연변이가 확인된 것은 획기적인 발전이었습니다. 위험군에 대한 유전자 검사를 통해 조기 발견 및 예방적 갑상선 절제술을 시행할 수 있으며, 이를 통해 생존율을 획기적으로 개선할 수 있는 것으로 나타났습니다. 체세포 RET 돌연변이와 RAS 돌연변이는 종양 거동과 잠재적 치료 반응에 대한 인사이트를 제공합니다. 유전자 프로파일을 기반으로 환자를 계층화할 수 있게 됨에 따라 치료 접근 방식과 후속 조치 프로토콜을 보다 개별화할 수 있게 되었습니다. 분자진단법은 또한 기존의 영상 진단이나 세포검사로 결론을 내릴 수 없는 경우, 갑상선 결절의 양성과 악성을 쉽게 감별할 수 있습니다. 액체생검법은 아직 시작 단계에 불과하지만, 비침습적으로 질병의 진행과 재발을 모니터링하는 데 유망 방법입니다. 이러한 분자생물학적 지식은 칼시토닌이나 CEA와 같은 혈청 바이오마커에 의해 보완됩니다. 또한 유전상담은 유전성 MTC 환자 치료에 있으며, 중요한 요소로 가족 전체에 대한 위험 평가와 예방 전략을 가능하게 합니다. 정밀의학이 계속 발전하고 있는 가운데, 유전학적 및 분자학적 데이터의 통합은 진단 정확도를 더욱 향상시키고, 공격적인 갑상선암 환자의 개별화된 관리를 개선할 수 있을 것으로 기대됩니다.

치료 상황의 변화에서 표적치료제와 신약은 어떤 역할을 하는가?

갑상선 수질암의 치료 상황은 표적 치료와 신약 개발의 출현으로 완전히 바뀌었습니다. 진행성, 수술 불가능 또는 전이성 MTC 환자의 경우, 기존의 화학요법이나 방사선 치료는 효과에 한계가 있으며, 보다 효과적인 전신 치료법을 모색하고 있습니다. 반데타닙, 카보잔티닙과 같은 티로신 키나아제 억제제(TKI)는 이러한 경우, 특히 진행성 환자들을 위한 최전선 치료제로 등장했습니다. 이들 약제는 RET 및 종양 성장과 혈관신생에 관여하는 다른 경로를 억제하여 무진행생존기간 연장 및 병세 조절을 가져옵니다. 최근에는 셀루페르티닙이나 프랄세티닙과 같은 고선택적 RET 억제제가 특히 RET 돌연변이 종양 환자에서 표적 외 효과가 적은 유의미한 임상적 효과를 보이고 있습니다. 이러한 약물은 정밀 종양학에서 중요한 진전이며, 임상의가 환자의 특정 유전적 변화에 맞게 치료를 조정할 수 있게 해주기 때문입니다. 현재 진행 중인 임상시험에서는 현재 치료제에 대한 내성을 극복하기 위한 병용요법, 면역요법, 기타 새로운 약제들이 검토되고 있습니다. 이러한 발전에도 불구하고 치료의 부작용과 최종적인 질병 진행의 위험은 여전히 과제이며, 지속적인 모니터링과 치료 전략의 조정이 필요합니다. 또한 이러한 치료법에 대한 접근성은 의료 인프라와 보험 적용 범위에 따라 달라질 수 있으며, 지역에 따라 치료 결과에 영향을 미칠 수 있습니다. 연구로 인해 표적치료제가 확대되면서 진행성 MTC 환자의 전망은 개선되고 있지만, 장기적인 관리를 위해서는 유효성, 안전성, QOL의 균형을 신중하게 고려해야 합니다.

갑상선 수질암 시장의 성장과 혁신을 촉진하는 주요 요인은?

갑상선 수질암 시장의 성장은 진단 기술 혁신, 의약품 개발, 환자 인식 개선, 의료 인프라 확충과 관련된 여러 가지 힘이 교차하면서 이루어집니다. 첫째, 정기적인 경부 초음파 검사와 세침흡입 생검의 보급으로 갑상선 결절의 조기 발견이 가능해졌고, 그 중 일부는 후속 분자 생화학 검사를 통해 MTC로 확인됩니다. 둘째, MEN 2와 같은 유전성 증후군에 대한 의사와 일반인의 인식이 높아지면서 유전 상담과 고위험군 가족에 대한 조기 검진에 대한 수요가 증가하고 있습니다. 셋째, 유전체학과 정밀의료의 지속적인 발전은 생존 예후를 개선하고 진행성 질환 환자에게 새로운 희망을 주는 표적치료제 개발에 박차를 가하고 있습니다. 넷째, 제약사들의 희귀질환 치료제 개발에 대한 투자가 MTC와 같은 희귀암 치료제의 연구와 상용화를 촉진하여 보다 탄탄한 치료 파이프라인을 만들어내고 있습니다. 다섯째, 디지털 헬스 툴과 환자 지원 플랫폼의 보급으로 세컨드 오피니언에 대한 접근, 임상시험 참여, 더 나은 치료 관리가 가능해졌습니다. 여섯째, 신흥 국가의 의료 접근성이 확대되면서 격차는 여전히 존재하지만, 진단율과 치료율이 점차 향상되고 있습니다. 일곱째, 패스트트랙 지정과 희귀질환 치료제 승인을 통한 규제 당국의 지원으로 새로운 치료제가 출시되는 시간이 빨라지고 있습니다. 마지막으로 내분비학, 종양학, 유전학, 외과를 통합한 다학제적 치료 모델은 협동적이고 종합적인 치료를 통해 환자의 예후를 개선하고 있습니다. 이러한 시장 성장 촉진요인은 전체적으로 갑상선 수질암 환자의 진단, 치료 및 삶의 질 향상에 초점을 맞춘 성장하고 점점 더 정교해지는 시장을 지원하고 있습니다.

부문

치료(외과 치료, 방사선 치료, 화학요법 치료); 최종 용도(병원, 방사선 치료 센터, 암연구기관)

조사 대상 기업의 예

  • AstraZeneca PLC
  • Bayer AG
  • BeOne Medicines
  • Blueprint Medicines
  • Crinetics Pharmaceuticals
  • Eli Lilly and Company
  • Epizyme, Inc.
  • Exelixis, Inc.
  • F. Hoffmann-La Roche Ltd
  • GSK(GlaxoSmithKline)
  • Ipsen
  • Janssen(Johnson & Johnson)
  • Jiangsu Hengrui Medicine
  • Loxo Oncology(Eli Lilly subsidiary)
  • Millennium Pharmaceuticals(Takeda)
  • Novo Nordisk
  • Pfizer Inc.
  • Rigel Pharmaceuticals
  • Sanofi AG
  • Takeda Pharmaceutical Company

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 일반적인 LLM나 업계 고유 SLM에 쿼리 하는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 대량 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.08.28

Global Medullary Thyroid Cancer Market to Reach US$2.2 Billion by 2030

The global market for Medullary Thyroid Cancer estimated at US$1.4 Billion in the year 2024, is expected to reach US$2.2 Billion by 2030, growing at a CAGR of 7.6% over the analysis period 2024-2030. Surgery Treatment, one of the segments analyzed in the report, is expected to record a 8.9% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Radiation Therapy Treatment segment is estimated at 5.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$383.3 Million While China is Forecast to Grow at 12.1% CAGR

The Medullary Thyroid Cancer market in the U.S. is estimated at US$383.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$468.0 Million by the year 2030 trailing a CAGR of 12.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.7% and 7.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Medullary Thyroid Cancer Market - Key Trends & Drivers Summarized

What Makes Medullary Thyroid Cancer Unique Among Thyroid Malignancies?

Medullary thyroid cancer (MTC) stands out as a distinct and relatively rare form of thyroid malignancy, accounting for approximately 3 to 4 percent of all thyroid cancer cases worldwide. Unlike the more common papillary and follicular thyroid cancers, which originate from follicular cells, MTC arises from parafollicular C cells that produce the hormone calcitonin. This unique origin gives MTC a different biological behavior, clinical presentation, and treatment approach. MTC can occur sporadically or as part of inherited syndromes such as multiple endocrine neoplasia type 2 (MEN 2), making genetic testing a cornerstone of diagnosis and risk stratification. The presence of elevated calcitonin and carcinoembryonic antigen (CEA) levels serves as important biomarkers for early detection and disease monitoring. Unlike differentiated thyroid cancers, MTC does not typically absorb radioactive iodine, limiting the effectiveness of traditional thyroid cancer therapies. Surgical resection remains the primary curative intervention, often involving total thyroidectomy and lymph node dissection. However, the disease’s propensity for early lymphatic spread and distant metastasis, especially to the liver and lungs, complicates long-term management. Additionally, patients with inherited forms often present at a younger age and may develop other endocrine tumors, further increasing clinical complexity. These factors underscore the need for early diagnosis, tailored treatment strategies, and lifelong monitoring, making MTC one of the most challenging thyroid cancers to manage clinically.

How Are Advances in Molecular Biology and Genetic Testing Reshaping Diagnosis and Risk Assessment?

The understanding of medullary thyroid cancer has been significantly enhanced by advances in molecular biology and genetic testing, which have become integral to both diagnosis and risk assessment. The identification of mutations in the RET proto-oncogene has been a landmark development, particularly in cases associated with familial syndromes such as MEN 2A and MEN 2B. Genetic screening of at-risk individuals allows for early detection and prophylactic thyroidectomy, which has been shown to dramatically improve survival outcomes. In sporadic cases, somatic RET mutations and RAS mutations offer insights into tumor behavior and potential therapeutic responses. The ability to stratify patients based on their genetic profiles has led to more personalized treatment approaches and follow-up protocols. Molecular diagnostics also facilitate differentiation between benign and malignant thyroid nodules when traditional imaging and cytology are inconclusive. Liquid biopsy techniques, though still emerging, show promise for non-invasive monitoring of disease progression and recurrence. These molecular insights are complemented by serum biomarkers such as calcitonin and CEA, which serve as reliable indicators of tumor burden and treatment response. Furthermore, genetic counseling has become a critical component of care for patients with hereditary forms of MTC, allowing for family-wide risk assessment and preventive strategies. As precision medicine continues to evolve, the integration of genetic and molecular data is expected to further refine diagnostic accuracy and improve individualized management for patients with this aggressive form of thyroid cancer.

What Role Do Targeted Therapies and Novel Drugs Play in Changing the Treatment Landscape?

The treatment landscape for medullary thyroid cancer has undergone a transformative shift with the advent of targeted therapies and novel drug development. For patients with advanced, inoperable, or metastatic MTC, traditional chemotherapy and radiotherapy offer limited efficacy, prompting a search for more effective systemic treatments. Tyrosine kinase inhibitors (TKIs) such as vandetanib and cabozantinib have emerged as the frontline therapies in such cases, particularly for patients with progressive disease. These agents work by inhibiting RET and other pathways involved in tumor growth and angiogenesis, offering prolonged progression-free survival and disease control. More recently, highly selective RET inhibitors like selpercatinib and pralsetinib have demonstrated significant clinical benefits with fewer off-target effects, especially in patients with RET-mutant tumors. These drugs represent a significant advancement in precision oncology, as they allow clinicians to match treatment with a patient’s specific genetic alterations. Ongoing clinical trials are exploring combination therapies, immunotherapies, and other novel agents aimed at overcoming resistance to current treatments. Despite these advances, treatment side effects and the risk of eventual disease progression remain challenges, necessitating continuous monitoring and adjustment of therapeutic strategies. Additionally, access to these therapies can vary based on healthcare infrastructure and insurance coverage, influencing outcomes in different regions. As research continues to expand the arsenal of targeted treatments, the outlook for patients with advanced MTC is improving, though long-term management still requires a careful balance of efficacy, safety, and quality of life considerations.

What Are the Key Drivers Fueling Growth and Innovation in the Medullary Thyroid Cancer Market?

The growth in the medullary thyroid cancer market is driven by several intersecting forces related to diagnostic innovation, drug development, patient awareness, and healthcare infrastructure expansion. First, increased use of routine neck ultrasounds and fine-needle aspiration biopsies has led to earlier detection of thyroid nodules, some of which are identified as MTC through follow-up molecular and biochemical testing. Second, rising awareness of genetic syndromes like MEN 2 among physicians and the public has led to greater demand for genetic counseling and early screening in high-risk families. Third, ongoing advances in genomics and precision medicine are fueling the development of targeted therapies that improve survival outcomes and offer new hope to patients with advanced disease. Fourth, investment by pharmaceutical companies in orphan drug development is incentivizing research and commercialization of therapies for rare cancers like MTC, resulting in a more robust treatment pipeline. Fifth, the proliferation of digital health tools and patient advocacy platforms is enabling individuals to access second opinions, participate in clinical trials, and better manage their care. Sixth, expanding access to healthcare in emerging economies is gradually improving diagnosis and treatment rates, although disparities still exist. Seventh, regulatory support through fast-track designations and orphan drug approvals is accelerating the time to market for new treatments. Lastly, multidisciplinary care models integrating endocrinology, oncology, genetics, and surgery are enhancing patient outcomes through coordinated and comprehensive care. These drivers collectively support a growing and increasingly sophisticated market focused on improving diagnosis, treatment, and quality of life for patients affected by medullary thyroid cancer.

SCOPE OF STUDY:

The report analyzes the Medullary Thyroid Cancer market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment (Surgery Treatment, Radiation Therapy Treatment, Chemotherapy Treatment); End-Use (Hospitals End-Use, Radiation Therapy Center End-Use, Cancer Research Institutes End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • AstraZeneca PLC
  • Bayer AG
  • BeOne Medicines
  • Blueprint Medicines
  • Crinetics Pharmaceuticals
  • Eli Lilly and Company
  • Epizyme, Inc.
  • Exelixis, Inc.
  • F. Hoffmann-La Roche Ltd
  • GSK (GlaxoSmithKline)
  • Ipsen
  • Janssen (Johnson & Johnson)
  • Jiangsu Hengrui Medicine
  • Loxo Oncology (Eli Lilly subsidiary)
  • Millennium Pharmaceuticals (Takeda)
  • Novo Nordisk
  • Pfizer Inc.
  • Rigel Pharmaceuticals
  • Sanofi AG
  • Takeda Pharmaceutical Company

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Medullary Thyroid Cancer - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Awareness and Early Diagnosis Efforts Throw the Spotlight on Medullary Thyroid Cancer Detection Pathways
    • Advances in Genetic Screening Propel Growth in RET Mutation Testing and Targeted Therapy Eligibility
    • Increased Incidence of Sporadic and Hereditary MTC Expands the Addressable Market Opportunity for Targeted Therapeutics
    • Approvals of RET Inhibitors Strengthen the Business Case for Precision Medicine in MTC Management
    • Expansion of Next-Generation Sequencing (NGS) in Oncology Accelerates Demand for Molecular Diagnostic Solutions
    • Unmet Needs in Late-Stage and Metastatic MTC Drive Clinical Interest in Novel Combination Therapies
    • Growing Role of Multidisciplinary Care Models Sustains Demand for Coordinated Treatment Planning Tools
    • Tele-oncology and Remote Monitoring Trends Enhance Access to Specialist Care for MTC Patients in Underserved Regions
    • Pharmaceutical Innovation in Kinase Inhibitors Generates New Hope for Progressive or Refractory MTC Cases
    • Increased Use of Biomarkers like Calcitonin and CEA Drives Growth in Longitudinal Monitoring Solutions
    • Global Expansion of Cancer Genomics Programs Opens New Pathways for MTC Identification and Stratified Treatment
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Medullary Thyroid Cancer Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Medullary Thyroid Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Medullary Thyroid Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Surgery Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Surgery Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Surgery Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Radiation Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Radiation Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Radiation Therapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Chemotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Chemotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Chemotherapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Radiation Therapy Center End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Radiation Therapy Center End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Radiation Therapy Center End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Cancer Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Cancer Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Cancer Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • JAPAN
    • Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • CHINA
    • Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • EUROPE
    • Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Medullary Thyroid Cancer by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Medullary Thyroid Cancer by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • FRANCE
    • Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • GERMANY
    • Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Medullary Thyroid Cancer by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Medullary Thyroid Cancer by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • INDIA
    • Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Medullary Thyroid Cancer by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Medullary Thyroid Cancer by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Medullary Thyroid Cancer by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Medullary Thyroid Cancer by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030
  • AFRICA
    • Medullary Thyroid Cancer Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Medullary Thyroid Cancer by Treatment - Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Medullary Thyroid Cancer by Treatment - Percentage Breakdown of Value Sales for Surgery Treatment, Radiation Therapy Treatment and Chemotherapy Treatment for the Years 2014, 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Medullary Thyroid Cancer by End-Use - Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Medullary Thyroid Cancer by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Radiation Therapy Center End-Use and Cancer Research Institutes End-Use for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제